

Special Issue

Advances in Anti-Influenza Drug Discovery and Treatment

Message from the Guest Editors

This Special Issue, titled “Advances in Anti-Influenza Drug Discovery and Treatment”, will be devoted to the development of new treatment options against influenza infections and the identification of novel therapeutic targets. To gain a comprehensive insight into progress and research, the journal *Viruses* invites experts in the field to contribute research articles or reviews.

Keywords:

- influenza virus
- anti-influenza agents
- drug discovery
- clinical studies
- identification of novel targets

Guest Editors

Dr. Kornelia Hardes

Fraunhofer Institute for Molecular Biology and Applied Ecology IME,
Giessen, Germany

Dr. Volker Czudai-Matwich

Fraunhofer Institute for Molecular Biology and Applied Ecology IME,
Giessen, Germany

Deadline for manuscript submissions

closed (30 September 2022)



Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/111758

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/

viruses





Viruses

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
viruses](https://mdpi.com/journal/viruses)



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research,
National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).